In AML, the promoter regions of both HLA-DRA and HLA-DPA1 display low acetylation (H3K9-14), presence of HDAC2 and absence of HATs such as p300, which has a predicted binding. This evidence concerns the gene EP300 and acute myeloid leukemia.